LOS ANGELES COUNTY
UCLA Brain Bank: HBSFRC
The Human Brain and Spinal Fluid Resource Center
11301 Wilshire Blvd. (127A)
Building 212 Room 16
Los Angeles, CA 90073
“Gift of Hope” Donor Entry Form:
EMERGENCY 24 hour pager: (310) 389-5199
General Inquiries: email@example.com
To become an organ donor for research, one can enroll in the Center’s “Gift of Hope” Anatomical Donor Program, which is a part of the UCLA Brain Bank. Enrolling in the “Gift of Hope” Program allows the Center’s personnel to make arrangements for tissue harvesting upon death, which will expedite the donation process. Pre-enrollment is not required, but is recommended because tissue is most beneficial to scientists when the time between death and tissue removal is kept as short as possible. Pre-enrollment is not binding; and a decision to donate can be changed. There is no cost to the donor or the donor’s family.
It is important to have the tissue removed as quickly as possible, before embalming, if embalming is planned. When a brain donor dies, the family or a member of the medical team who cared for the donor should call the Center’s Coordinator. During office hours, (310) 268-3536; 24 hour pager (310) 636-5199. In the unlikely event that you do not receive a response when paging, please call the VA switchboard at (310) 478-3711. They will provide additional phone numbers to reach the center.
SAN DIEGO COUNTY
Shiley-Marcos Alzheimer’s Disease Research Center
University of California San Diego
9500 Gilman Drive
La Jolla, CA 92093-0949
Contact: Dr. Eliezer Masliah
Phone: (858) 534-6212
This brain bank rarely accepts de-novo donations, instead drawing on its Alzheimer’s research center, which follows patients longitudinally.
Dementia with Lewy Bodies Consortium at UC San Diego School of Medicine
For further information, contact Veronica Lopez at:
858-822-5786 or firstname.lastname@example.org
The purpose of this study is to develop a collection of samples from individuals diagnosed with Lewy body dementia (DLB) or Lewy body dementia/MCI (mild cognitive impairment) who will be followed over a period of 5 years. The consortium will collect detailed clinical information, biospecimens, and imaging data. Led by top leaders in the field, this consortium will fill the gap in resources available for biomarker development in DLB and promote additional future research, including therapeutic trials, by having a readily available subject sample.